Skip to main content

Table 6 Summary of findings table for abacavir-containing cART regimens compared to cART regimens containing zidovudine or stavudine (cohort studies)

From: Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

Outcomes Illustrative comparative risks* (95 % CI) Relative effect (95 % CI) No of Participants (studies) Quality of the evidence (GRADE)
Assumed risk Corresponding risk
AZT or d4T - containing combination antiretroviral regimens ABC -containing combination antiretroviral regimens
Virologic suppression - Lopinavir/ ritonavir based (VL < 50 copies/ml) 516 per 1000 408 per 1000 RR 0.79 2165
Follow-up: mean 48 weeks (346–475) (0.67–0.92) (1 study) low
Virologic failure 211 per 1000 213 per 1000 RR 1.01 557
Follow-up: mean 24 months (154–294) (0.73–1.39) (1 study) low
Death 35 per 1000 25 per 1000 RR 0.72 557
Follow-up: mean 24 months (9–67) (0.27–1.92) (1 study) low
  1. * The corresponding risk (and its 95% confidence interval) is based on the assumed risk in thecomparison group and the relative effect of the intervention (and its 95% CI)